Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

By N. Flynn, D. Forthal, Clayton D. Harro, F. Judson, K. Mayer, M. Para. Journal of Infectious Diseases, 2005

976 citations recorded by the source corpus.

Subfields: Infectious Diseases, Virology

View Paper: https://www.semanticscholar.org/paper/c6040bda245ac894aa31ee01692a12a1c652ee13

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Ian A. Wilson
2. Abdo A. Elfiky

Citations in the corpus

• A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies (2013, background): “Of these, the most widely tested have been monomeric gp120 subunits, which failed to induce bNAbs and did not prevent infection [2,3,4].”